Brief: Abbisko Cayman Says Unit Entered A Worldwide Collaboration And Exclusive Licensing Deal With Eli Lilly
18/01/2022 01:03
Jan 18 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* UNIT ENTERED INTO A WORLDWIDE COLLABORATION AND EXCLUSIVE
LICENSING AGREEMENT WITH ELI LILLY AND CO
* DEAL FOR FURTHER DEVELOPMENT & POTENTIAL COMMERCIALIZATION
OF
NOVEL MOLECULES AGAINST UNDISCLOSED TARGET FOR CARDIOMETABOLIC
DISEASES
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration